Treatment of Newly Diagnosed Ovarian Cancer With Antioxidants

• Status: Completed
• Trial end date: 2007-08-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to try and understand if there is added benefit or increased harm when antioxidant nutritional supplements are added to traditional chemotherapy in the treatment of ovarian cancer.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Jeanne Drisko, MD, CNS, FACN
• Collaborators: Cancer Treatment Research Foundation; University of Kansas Medical Center
• Treatments: Albumin-Bound Paclitaxel; alpha-Tocopherol; Antioxidants; Ascorbic Acid; Carboplatin; Carotenoids; Paclitaxel; Retinol palmitate; Tocopherols; Tocotrienols; Vitamin A; Vitamin E; Vitamins

Criteria

Inclusion Criteria:

• histologically confirmed carcinoma of the ovary stage III or IV

• measurable or assessable disease

• drug refractory ovarian cancer

• must be 18 years of age or must have parental consent to enroll in the study

• must be ambulatory

Exclusion Criteria:

• evidence of significant psychiatric disorder by history or exam

• consumption of excess alcohol (more than 4 of any of the following per day: 30 ml distilled spirits, 340 ml beer, or 120 ml wine) or recreational drugs

• tobacco use

• prior treatment with an investigational drug, chemo, radiation therapy, or hormonal therapy within the preceeding month

• pregnancy